Holen Sie sich die Stockscreener-App
0.8817
4.98%
-0.0462
Handel nachbörslich:
.90
0.0183
+2.08%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.9279
Offen:
$0.96
24-Stunden-Volumen:
2.10M
Relative Volume:
1.20
Marktkapitalisierung:
$166.23M
Einnahmen:
$154.90M
Nettoeinkommen (Verlust:
$-20.20M
KGV:
-7.317
EPS:
-0.1205
Netto-Cashflow:
$-27.91M
1W Leistung:
-8.78%
1M Leistung:
-23.33%
6M Leistung:
-30.02%
1J Leistung:
-62.00%
1-Tages-Spanne:
$0.88
$0.96
1-Wochen-Bereich:
$0.88
$1.045
52-Wochen-Spanne:
$0.88
$2.61
Heron Therapeutics Inc Stock (HRTX) Company Profile
Firmenname
Heron Therapeutics Inc
Sektor
Branche
Telefon
(858) 251-4400
Adresse
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
0.8817 | 174.94M | 154.90M | -20.20M | -27.91M | -0.1205 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-04-23 | Eingeleitet | CapitalOne | Overweight |
| 2024-03-13 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Buy |
| 2020-02-20 | Bestätigt | Needham | Buy |
| 2019-01-16 | Bestätigt | Needham | Buy |
| 2018-04-05 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2018-03-01 | Bestätigt | Needham | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Outperform |
| 2017-09-27 | Eingeleitet | Northland Capital | Outperform |
| 2017-02-27 | Eingeleitet | Needham | Buy |
| 2016-10-26 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-06 | Fortgesetzt | Lake Street | Buy |
| 2016-05-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-10 | Eingeleitet | Lake Street | Buy |
| 2015-09-23 | Bestätigt | Leerink Partners | Outperform |
| 2015-09-02 | Eingeleitet | BofA/Merrill | Buy |
| 2015-08-03 | Bestätigt | Brean Capital | Buy |
| 2015-06-30 | Bestätigt | JMP Securities | Mkt Outperform |
| 2015-06-19 | Bestätigt | Leerink Partners | Outperform |
| 2014-08-07 | Eingeleitet | Noble Financial | Buy |
Alle ansehen
Heron Therapeutics Inc Aktie (HRTX) Neueste Nachrichten
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Citigroup Inc. Increases Stock Position in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron Therapeutics Signals Profitable Growth After Strong Quarter - TipRanks
Earnings Call Summary | Heron Therapeutics(HRTX.US) Q4 2025 Earnings Conference - 富途牛牛
What is Northland Securities' Forecast for HRTX Q1 Earnings? - MarketBeat
HC Wainwright Has Negative Forecast for HRTX FY2026 Earnings - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
HRTX Should I Buy - Intellectia AI
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2025 Earnings Call Transcript - Insider Monkey
What is HC Wainwright's Estimate for HRTX Q1 Earnings? - MarketBeat
HRTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Heron (HRTX) Q4 2025 Earnings Call Transcript - AOL.com
Heron Therapeutics: Profitable Growth Outlook and Acute Care Momentum Underpin Buy Rating and $3 Target - TipRanks
Heron Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Heron Therapeutics outlines $173M–$183M 2026 sales targets amid acute care momentum and expanded commercial investment - MSN
Heron Therapeutics Q4 Earnings Call Highlights - MarketBeat
Heron Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:HRTX) 2026-02-26 - Seeking Alpha
Key facts: Heron Therapeutics projects $173-$183M revenue by 2026; ZYNRELEF adoption rises; credit facilities expanded - TradingView
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Heron Therapeutics, Inc. Provides Earnings Guidance for the Year 2026 - marketscreener.com
Earnings call transcript: Heron Therapeutics Q4 2025 reports strong growth By Investing.com - Investing.com Canada
Heron Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
HRTX: 2025 net revenue rose 7.4% to $154.9M, with strong Acute Care growth and positive EBITDA - TradingView
HERON THERAPEUTICS ($HRTX) Releases Q4 2025 Earnings - Quiver Quantitative
Heron Therapeutics: Q4 Earnings Snapshot - Citizen Tribune
Heron Therapeutics: Fourth Quarter Earnings Overview - Bitget
HERON THERAPEUTICS, INC. /DE/ SEC 10-K Report - TradingView
Heron Therapeutics Q4 revenue dips as Acute Care segment holds fort - TradingView
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results - The Manila Times
HRTX: 2025 net revenue rose 7.4% to $154.9M, driven by Acute Care growth and new CMS J-Codes - TradingView
Aug Sectors: Whats Heron Therapeutics Incs historical returnWeekly Profit Recap & Technical Pattern Based Signals - baoquankhu1.vn
Heron Therapeutics Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Heron Therapeutics, Inc. (HRTX) Stock Analysis: Exploring A Potential Upside Of 258.13% - DirectorsTalk Interviews
Heron Therapeutics, Inc. $HRTX Shares Acquired by JW Asset Management LLC - MarketBeat
Heron Therapeutics (HRTX) Expected to Announce Earnings on Thursday - MarketBeat
Aug EndMonth: What are JOFF Fintech Acquisition Corp Debt Equity Composite Unitss growth leversMarket Trend Report & Verified Entry Point Detection - baoquankhu1.vn
MSN Money - MSN
Heron: Near The Bottom Of A Trading Range Despite Positives (NASDAQ:HRTX) - Seeking Alpha
Clearline Capital reports 6.7% Heron Therapeutics stake (HRTX) - Stock Titan
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 - The Manila Times
Should I set a stop loss on Heron Therapeutics Inc.Dollar Strength & Entry Point Confirmation Signals - mfd.ru
Can Heron Therapeutics Inc. expand into new marketsWeekly Risk Report & Breakout Confirmation Trade Signals - mfd.ru
How does Heron Therapeutics Inc. compare to its peersJuly 2025 Weekly Recap & Community Consensus Trade Alerts - mfd.ru
How strong is Heron Therapeutics Inc. (AXD2) stock earnings growthJuly 2025 WrapUp & Safe Capital Growth Tips - mfd.ru
How resilient is Heron Therapeutics Inc. stock in market downturnsJuly 2025 Rallies & Free Accurate Trade Setup Notifications - mfd.ru
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Here's Why Heron Therapeutics (NASDAQ:HRTX) Has A Meaningful Debt Burden - simplywall.st
Is Heron Therapeutics Inc. impacted by rising rates2025 Market Outlook & Weekly Hot Stock Watchlists - mfd.ru
Is Heron Therapeutics Inc. stock a good dividend stock2025 Analyst Calls & Daily Technical Stock Forecast Reports - mfd.ru
Finanzdaten der Heron Therapeutics Inc-Aktie (HRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):